Comparative Pharmacology
Head-to-head clinical analysis: ACCOLATE versus ZAFIRLUKAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCOLATE versus ZAFIRLUKAST.
ACCOLATE vs ZAFIRLUKAST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective leukotriene receptor antagonist (LTRA) that inhibits the cysteinyl leukotriene (CysLT1) receptor, preventing bronchoconstriction, inflammation, and airway edema.
Zafirlukast is a selective and competitive receptor antagonist of cysteinyl leukotrienes (LTC4, LTD4, LTE4) at the CysLT1 receptor, inhibiting bronchoconstriction, mucus secretion, and airway inflammation.
20 mg orally twice daily, 1 hour before or 2 hours after meals.
20 mg orally twice daily, 1 hour before or 2 hours after meals.
None Documented
None Documented
Terminal elimination half-life is 10–20 hours (mean ~15 hours) in healthy adults; prolonged in hepatic impairment.
Clinical Note
moderateZafirlukast + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Zafirlukast."
Clinical Note
moderateZafirlukast + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Zafirlukast."
Clinical Note
moderateZafirlukast + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Zafirlukast."
Clinical Note
moderateZafirlukast + Fluconazole
Terminal elimination half-life is approximately 10 hours in healthy adults, allowing twice-daily dosing. Half-life may be prolonged in patients with hepatic impairment (e.g., cirrhosis) but is not significantly affected by renal impairment.
Primarily hepatic metabolism via CYP2C9; 87% excreted in feces, 10% in urine as metabolites. Less than 1% excreted unchanged.
Zafirlukast is primarily eliminated by hepatic metabolism, with less than 1% excreted unchanged in urine. Fecal excretion accounts for approximately 10% of the dose, primarily as metabolites.
Category C
Category A/B
Leukotriene Receptor Antagonist
Leukotriene Receptor Antagonist
"The metabolism of Fluconazole can be decreased when combined with Zafirlukast."